+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Complex Regional Pain Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Complex Regional Pain Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT2B Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2B Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT6 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT6 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
5-HT7 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT7 Antagonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Alpha-synuclein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-synuclein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Alpha-Synuclein (alphaSyn Or SNCA) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-Synuclein (alphaSyn Or SNCA) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Lebers Hereditary Optic Neuropathy (lhon) - Pipeline Insight, 2025 - Product Thumbnail Image

Lebers Hereditary Optic Neuropathy (lhon) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Restless Leg Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Restless Leg Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Dup15q Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Dup15q Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Primary Progressive Aphasia - Pipeline Insight, 2025 - Product Thumbnail Image

Primary Progressive Aphasia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Refractory Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Refractory Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Tay-Sachs Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Tay-Sachs Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Parkinson's Disease - Epidemiology Forecast - 2034 - Product Thumbnail Image

Parkinson's Disease - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 159 Pages
  • Global
From
Myasthenia Gravis - Epidemiology Forecast - 2034 - Product Thumbnail Image

Myasthenia Gravis - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 143 Pages
  • Global
From
Dementia with Lewy Bodies (DLB) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Dementia with Lewy Bodies (DLB) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 88 Pages
  • Global
From
From
Traumatic Brain Injury - Epidemiology Forecast - 2034 - Product Thumbnail Image

Traumatic Brain Injury - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more